Forte Capital LLC ADV Purchases New Position in Repligen Co. (NASDAQ:RGEN)

Forte Capital LLC ADV purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,139 shares of the biotechnology company’s stock, valued at approximately $205,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. raised its position in Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares during the period. Signaturefd LLC raised its position in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 86 shares during the period. Milestone Investment Advisors LLC purchased a new stake in Repligen during the third quarter valued at approximately $61,000. Headlands Technologies LLC purchased a new stake in Repligen during the third quarter valued at approximately $75,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Repligen by 67.6% in the third quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company’s stock worth $85,000 after buying an additional 215 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Trading Up 0.4 %

RGEN traded up $0.74 during trading on Friday, hitting $167.05. 454,984 shares of the stock were exchanged, compared to its average volume of 538,521. The firm has a 50 day simple moving average of $180.81 and a 200 day simple moving average of $174.09. The firm has a market cap of $9.33 billion, a price-to-earnings ratio of 668.23, a P/E/G ratio of 5.46 and a beta of 1.03. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 6.35.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to the consensus estimate of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm’s revenue was down 17.1% compared to the same quarter last year. During the same period last year, the business posted $0.64 EPS. As a group, equities analysts expect that Repligen Co. will post 1.46 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RGEN. JPMorgan Chase & Co. reduced their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday. KeyCorp increased their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Finally, Stifel Nicolaus increased their price target on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus price target of $197.75.

Insider Buying and Selling at Repligen

In other news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is currently owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.